N Picard

Summary

Affiliation: CHU Dupuytren
Country: France

Publications

  1. doi Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse
    Alaa Al Saabi
    EA4483, Faculty of Medicine, Universite Lille Nord de France, Lille, France
    Drug Metab Dispos 41:568-74. 2013
  2. pmc The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics
    N Picard
    INSERM U850, Limoges, France
    Clin Pharmacol Ther 87:100-8. 2010
  3. ncbi Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5
    Nicolas Picard
    Laboratoire de Pharmacologie Medicale, EA 3838 DEXO, Facultéde Médecine, 2 rue du Dr Marcland, 87025 Limoges, France
    Drug Metab Dispos 35:350-5. 2007
  4. pmc CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients
    Nicolas Picard
    INSERM, UMR S 850, Limoges, France
    Transplantation 91:652-6. 2011
  5. doi Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters
    Nicolas Picard
    INSERM, UMR S850, Limoges, France
    Xenobiotica 41:752-7. 2011
  6. pmc Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up
    J B Woillard
    INSERM, UMR S 850, Limoges, France
    Clin Pharmacol Ther 88:95-100. 2010
  7. pmc Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele
    Jean Baptiste Woillard
    INSERM, UMR S 850, Limoges, France
    Br J Clin Pharmacol 69:675-83. 2010
  8. doi Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients
    Khaled Benkali
    INSERM U850, University of Limoges, Limoges, France
    Clin Pharmacokinet 48:805-16. 2009
  9. ncbi [Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation]
    P Marquet
    Service de pharmacologie toxicologie, CHU Dupuytren, Limoges Cedex, France
    Ann Pharm Fr 65:382-9. 2007
  10. doi Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes
    Koukeb Rouguieg
    INSERM, Unité Mixte de Recherche S 850, Limoges, France
    Drug Metab Dispos 38:40-5. 2010

Collaborators

Detail Information

Publications18

  1. doi Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse
    Alaa Al Saabi
    EA4483, Faculty of Medicine, Universite Lille Nord de France, Lille, France
    Drug Metab Dispos 41:568-74. 2013
    ..17 mg/l; inhibition constant (K(i)) = 3.1 mg/l). UGT1A9 and 2B7 are the main enzymes involved in ethanol glucuronidation. In addition, our results suggest that cannabinol and cannabidiol could significantly alter ethanol glucuronidation...
  2. pmc The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics
    N Picard
    INSERM U850, Limoges, France
    Clin Pharmacol Ther 87:100-8. 2010
    ..Further studies demonstrated that this variant of OATP1B3 exhibited a reduced maximal velocity (V(max)) in transfected HEK cells, thereby providing functional evidence to support our clinical findings...
  3. ncbi Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5
    Nicolas Picard
    Laboratoire de Pharmacologie Medicale, EA 3838 DEXO, Facultéde Médecine, 2 rue du Dr Marcland, 87025 Limoges, France
    Drug Metab Dispos 35:350-5. 2007
    ..In the absence of cyclosporine, the CYP 3A5*3 polymorphism may not influence significantly sirolimus metabolism at the hepatic level. However, strong CYP 3A4 inhibition by cyclosporine could unveil the influence of this polymorphism...
  4. pmc CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients
    Nicolas Picard
    INSERM, UMR S 850, Limoges, France
    Transplantation 91:652-6. 2011
    ..CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics...
  5. doi Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters
    Nicolas Picard
    INSERM, UMR S850, Limoges, France
    Xenobiotica 41:752-7. 2011
    ..In conclusion, our data suggest that the major OATP transporters expressed in the liver and the intestine do not contribute to the pharmacokinetics of sirolimus and everolimus. However, ImTORs are inhibitors of these transporters...
  6. pmc Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up
    J B Woillard
    INSERM, UMR S 850, Limoges, France
    Clin Pharmacol Ther 88:95-100. 2010
    ..186 mlxmin(-1)/year; P = 0.0240). The study showed that the presence of ABCB1 polymorphisms in donors influences long-term graft outcome adversely with decrease in renal function and graft loss in transplant recipients receiving CsA...
  7. pmc Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele
    Jean Baptiste Woillard
    INSERM, UMR S 850, Limoges, France
    Br J Clin Pharmacol 69:675-83. 2010
    ....
  8. doi Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients
    Khaled Benkali
    INSERM U850, University of Limoges, Limoges, France
    Clin Pharmacokinet 48:805-16. 2009
    ....
  9. ncbi [Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation]
    P Marquet
    Service de pharmacologie toxicologie, CHU Dupuytren, Limoges Cedex, France
    Ann Pharm Fr 65:382-9. 2007
    ..The pharmacogenetics of immunosuppressants is thus still an open field for investigations and potential therapeutic progress...
  10. doi Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes
    Koukeb Rouguieg
    INSERM, Unité Mixte de Recherche S 850, Limoges, France
    Drug Metab Dispos 38:40-5. 2010
    ..0352). This study represents a functional basis for further clinical pharmacogenetic studies...
  11. ncbi Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry
    Aurélie Prémaud
    Department of Pharmacology and Toxicology, Limoges University Hospital, Limoges, France
    Ther Drug Monit 28:274-7. 2006
    ..7 +/- 2 6.8% with EMIT, with variations depending on the time elapsed since transplantation. An EMIT overestimation of 16.7 +/- 22.5% also was obtained for the MPA areas under the curve calculated using the trapezoidal rule...
  12. doi Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase
    Olivier Gensburger
    INSERM UMR S850, Limoges, France
    Clin Chem 55:986-93. 2009
    ..We investigated the action of the MPA metabolites MPA-phenyl-glucuronide (MPAG) and MPA-acyl-glucuronide (AcMPAG) on recombinant human IMPDH II (rhIMPDH II), as well as their passage into lymphocytes in vitro...
  13. doi General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism
    Nicolas Picard
    INSERM, UMR S850, Limoges Cedex, France
    J Sep Sci 32:2209-17. 2009
    ..The GUS procedure used in this study may be applicable as a generic technique for the characterization of drug metabolites after in vitro incubation, as well as probably in vivo experiments...
  14. ncbi Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients
    Nassim Djebli
    Laboratory of Pharmacology, Faculty of Medicine, Limoges University, Limoges University Hospital, 2 Avenue Martin Luther King, 87042 Limoges, France
    Pharmacogenet Genomics 17:321-30. 2007
    ....
  15. pmc A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients
    Nicolas Picard
    Laboratory of Pharmacology, Faculty of Medicine, University of Limoges, France
    Br J Clin Pharmacol 62:477-84. 2006
    ..To compare the pharmacokinetics of mycophenolic acid when given with either ciclosporin or sirolimus, and investigate in vitro the potential effect of ciclosporin, sirolimus, tacrolimus and everolimus on mycophenolic acid metabolism...
  16. ncbi In vitro metabolism study of buprenorphine: evidence for new metabolic pathways
    Nicolas Picard
    Department of Medical Pharmacology, University of Limoges, France
    Drug Metab Dispos 33:689-95. 2005
    ..Incubation of BUP or Nor-BUP with HLM led to the formation of new metabolites, identified by tandem mass spectrometry as being hydroxy-BUP and hydroxy-Nor-BUP. Hydroxy-BUP was produced by the CYP 3A, but not the 2C isoforms...
  17. ncbi Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5
    Nicolas Picard
    Department of Pharmacology and Toxicology, University Hospital, 87042 Limoges, France
    Ther Drug Monit 26:600-8. 2004
    ..MPA might compete with other drugs on CYP3A because of its high therapeutic concentrations, although this was not the case for cyclosporin and to only a small extent for tacrolimus...
  18. ncbi Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism
    Nicolas Picard
    Department of Pharmacology Toxicology, University Hospital, 87042 Limoges, France
    Drug Metab Dispos 33:139-46. 2005
    ..In conclusion, UGT 1A9 and 2B7 were clearly identified as the main UGT isoforms involved in mycophenolic acid glucuronidation, presumably due to their high hepatic and renal expression...